YN001
Phase 2Small molecule
YN001 is one of 60 small molecule programs targeting Erectile Dysfunction. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Erectile Dysfunction
#DrugCompanyPhaseTrials
1Levitra
BayerPhase 3
Zocor
OOrganon and Co
Phase 3
LCZ696
NovartisPhase 3
Botulinum Toxin a
GSKPhase 3
Platelet Rich Plasma
ZZagazig University
Phase 3
Fluvastatin XL
NovartisPhase 3
Stem Cells
KKang Stem Biotech Co., Ltd.
Phase 3
TPN171H
VVigonvita Life Sciences
Phase 3
Dapoxetine
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Papaverine
WWestern Galilee Hospital-Nahariya
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Erectile Dysfunction1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for YN001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBeijing Inno Medicine Co., Ltd.